Hubbry Logo
Interferon type IInterferon type IMain
Open search
Interferon type I
Community hub
Interferon type I
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Interferon type I
Interferon type I
Interferon type I
View on Wikipedia
from Wikipedia
Not to be confused with Interferon type II.
Interferon Type I (α/β/δ...)
The molecular structure of human interferon-beta (PDB: 1AU1​).
Identifiers
SymbolInterferons
PfamPF00143
InterProIPR000471
SMARTSM00076
PROSITEPDOC00225
CATH1au1
SCOP21au1 / SCOPe / SUPFAM
CDDcd00095
Available protein structures:
Pfam  structures / ECOD  
PDBRCSB PDB; PDBe; PDBj
PDBsumstructure summary
PDB1b5l :24-187 1ovi :24-185 2hie :24-186

1itf :24-186 1au1B:22-187 2hif :24-182

1wu3I:22-182

The type-I interferons (IFN) are cytokines which play essential roles in inflammation, immunoregulation, tumor cells recognition, and T-cell responses. In the human genome, a cluster of thirteen functional IFN genes is located at the 9p21.3 cytoband over approximately 400 kb including coding genes for IFNα (IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17 and IFNA21), IFNω (IFNW1), IFNɛ (IFNE), IFNк (IFNK) and IFNβ (IFNB1), plus 11 IFN pseudogenes.[1]

Interferons bind to interferon receptors. All type I IFNs bind to a specific cell surface receptor complex known as the IFN-α receptor (IFNAR) that consists of IFNAR1 and IFNAR2 chains.

Type I IFNs are found in all mammals, and homologous (similar) molecules have been found in birds, reptiles, amphibians and fish species.[2][3]

Sources and functions

[edit]

IFN-α and IFN-β are secreted by many cell types including lymphocytes (NK cells, B-cells and T-cells), macrophages, fibroblasts, endothelial cells, osteoblasts and others. They stimulate both macrophages and NK cells to elicit an anti-viral response, involving IRF3/IRF7 antiviral pathways,[4] and are also active against tumors. Plasmacytoid dendritic cells have been identified as being the most potent producers of type I IFNs in response to antigen, and have thus been coined natural IFN producing cells.[citation needed]

IFN-ω is released by leukocytes at the site of viral infection or tumors.[citation needed]

IFN-α acts as a pyrogenic factor by altering the activity of thermosensitive neurons in the hypothalamus thus causing fever. It does this by binding to opioid receptors and eliciting the release of prostaglandin-E2 (PGE2).[citation needed]

A similar mechanism is used by IFN-α to reduce pain; IFN-α interacts with the μ-opioid receptor to act as an analgesic.[5]

In mice, IFN-β inhibits immune cell production of growth factors, thereby slowing tumor growth, and inhibits other cells from producing vessel-producing growth factors, thereby blocking tumor angiogenesis and hindering the tumour from connecting into the blood vessel system.[6]

In both mice and human, negative regulation of type I interferon signaling is known to be important. Few endogenous regulators have been found to elicit this important regulatory function, such as SOCS1 and Aryl Hydrocarbon Receptor Interacting Protein (AIP).[7]

Mammalian types

[edit]

The mammalian types are designated IFN-α (alpha), IFN-β (beta), IFN-κ (kappa), IFN-δ (delta), IFN-ε (epsilon), IFN-τ (tau), IFN-ω (omega), and IFN-ζ (zeta, also known as limitin).[8][9] Of these types, IFN-α, IFN -ω, and IFN-τ can work across species.[10]

IFN-α

[edit]

The IFN-α proteins are produced mainly by plasmacytoid dendritic cells (pDCs). They are mainly involved in innate immunity against viral infection. The genes responsible for their synthesis come in 13 subtypes that are called IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16, IFNA17, IFNA21. These genes are found together in a cluster on chromosome 9. By comparison, in other species such as mice, mouse IFN-α genes were first isolated and characterized in 1982 by Shaw in the Weissmann lab at the University of Zurich. There are 14 mouse IFN-α genes and they are found in a cluster on chromosome 4.[11][12]

IFN-α is also made synthetically as medication in hairy cell leukemia. The International Nonproprietary Name (INN) for the product is interferon alfa. The recombinant type is interferon alfacon-1. The pegylated types are pegylated interferon alfa-2a and pegylated interferon alfa-2b.

Recombinant feline interferon omega is a form of cat IFN-α (not ω) for veterinary use.[10]

IFN-β

[edit]

The IFN-β proteins are produced in large quantities by fibroblasts and play a key role in the innate immune response through their antiviral activity. Only one type of IFN-β, IFN-β1 (IFNB1), has been confirmed. A second gene, IFNB3, was reported,[13] but this symbol was never adopted by the HUGO Gene Nomenclature Committee. A third gene once designated IFN-β2 was later identified as IL-6.

IFN-ε, -κ, -τ, -δ and -ζ

[edit]

IFN-ε, -κ, -τ, and -ζ appear, at this time, to come in a single isoform in humans, IFNK. Only ruminants encode IFN-τ, a variant of IFN-ω. So far, IFN-ζ is only found in mice, while a structural homolog, IFN-δ is found in a diverse array of non-primate and non-rodent placental mammals. Most but not all placental mammals encode functional IFN-ε and IFN-κ genes.[citation needed].

IFN-ω

[edit]

IFN-ω, although having only one functional form described to date (IFNW1), has several pseudogenes: IFNWP2, IFNWP4, IFNWP5, IFNWP9, IFNWP15, IFNWP18, and IFNWP19 in humans. Many non-primate placental mammals express multiple IFN-ω subtypes.

IFN-ν

[edit]
Not to be confused with Interferon gamma or IFN-γ.

This subtype of type I IFN was recently described as a pseudogene in human, but potentially functional in the domestic cat genome. In all other genomes of non-feline placental mammals, IFN-ν is a pseudogene; in some species, the pseudogene is well preserved, while in others, it is badly mutilated or is undetectable. Moreover, in the cat genome, the IFN-ν promoter is deleteriously mutated. It is likely that the IFN-ν gene family was rendered useless prior to mammalian diversification. Its presence on the edge of the type I IFN locus in mammals may have shielded it from obliteration, allowing its detection.[citation needed]

Interferon type I in cancer

[edit]

Therapeutics

[edit]

From the 1980s onward, members of type-I IFN family have been the standard care as immunotherapeutic agents in cancer therapy. In particular, IFNα has been approved by the US Food and Drug Administration (FDA) for cancer. To date, pharmaceutical companies produce several types of recombinant and pegylated IFNα for clinical use; e.g., IFNα2a (Roferon-A, Roche), IFNα2b (Intron-A, Schering-Plough) and pegylated IFNα2b (Sylatron, Schering Corporation) for treatment of hairy cell leukemia, melanoma, renal cell carcinoma, Kaposi's sarcoma, multiple myeloma, follicular and non-Hodgkin lymphoma, and chronic myelogenous leukemia. Human IFNβ (Feron, Toray ltd.) has also been approved in Japan to treat glioblastoma, medulloblastoma, astrocytoma, and melanoma.[1]

Copy number alteration of the interferon gene cluster in cancer

[edit]

A large individual patient data meta-analysis using 9937 patients obtained from cBioportal indicates that copy number alteration of the IFN gene cluster is prevalent among 24 cancer types. Notably deletion of this cluster is significantly associated with increased mortality in many cancer types particularly uterus, kidney, and brain cancers. The Cancer Genome Atlas PanCancer analysis also showed that copy number alteration of the IFN gene cluster is significantly associated with decreased overall survival. For instance, the overall survival of patients with brain glioma reduced from 93 months (diploidy) to 24 months. In conclusion, the copy number alteration of the IFN gene cluster is associated with increased mortality and decreased overall survival in cancer.[1]

Use of Interferon type I in therapeutics

[edit]

In cancer

[edit]

From the 1980s onward, members of type-I IFN family have been the standard care as immunotherapeutic agents in cancer therapy. In particular, IFNα has been approved by the US Food and Drug Administration (FDA) for cancer. To date, pharmaceutical companies produce several types of recombinant and pegylated IFNα for clinical use; e.g., IFNα2a (Roferon-A, Roche), IFNα2b (Intron-A, Schering-Plough) and pegylated IFNα2b (Sylatron, Schering Corporation) for treatment of hairy cell leukemia, melanoma, renal cell carcinoma, Kaposi's sarcoma, multiple myeloma, follicular and non-Hodgkin lymphoma, and chronic myelogenous leukemia. Human IFNβ (Feron, Toray ltd.) has also been approved in Japan to treat glioblastoma, medulloblastoma, astrocytoma, and melanoma.[1]

Combinational therapy with PD-1/PD-L1 inhibitors

[edit]

By combining PD-1/PD-L1 inhibitors with type I interferons, researchers aim to tackle multiple resistance mechanisms and enhance the overall anti-tumor immune response. The approach is supported by preclinical and clinical studies that show promising synergistic effects, particularly in melanoma and renal carcinoma. These studies reveal increased infiltration and activation of T cells within the tumor microenvironment, the development of memory T cells, and prolonged patient survival.[14]

In viral infection

[edit]

Due to their strong antiviral properties, recombinant type 1 IFNs can be used for the treatment for persistent viral infection. Pegylated IFN-α is the current standard of care when it comes to chronic Hepatitis B and C infection.[15]

In multiple sclerosis

[edit]

Currently, there are four FDA approved variants of IFN-β1 used as a treatment for relapsing multiple sclerosis.[16] IFN-β1 is not an appropriate treatment for patients with progressive, non-relapsing forms of multiple sclerosis.[17] Whilst the mechanism of action is not completely understood, the use of IFN-β1 has been found to reduce brain lesions, increase the expression of anti-inflammatory cytokines and reduce T cell infiltration into the brain.[18][19]

Side effects of type I interferon therapy

[edit]

One of the major limiting factors in the efficacy of type I interferon therapy are the high rates of side effects. Between 15% - 40% of people undergoing type 1 IFN treatment develop major depressive disorders.[20] Less commonly, interferon treatment has also been associated with anxiety, lethargy, psychosis and parkinsonism.[21] Mood disorders associated with IFN therapy can be reversed by discontinuation of treatment, and IFN therapy related depression is effectively treated with the selective serotonin reuptake inhibitor class of antidepressants.[22]

Interferonopathies

[edit]

Interferonopathies are a class of hereditary auto-inflammatory and autoimmune diseases characterised by upregulated type 1 interferon and downstream interferon stimulated genes. The symptoms of these diseases fall in a wide clinical spectrum, and often resemble those of viral infections acquired while the child is in utero, although lacking any infectious origin.[23] The aetiology is largely still unknown, but the most common genetic mutations are associated with nucleic acid regulation, leading most researchers to suggest these arise from the failure of antiviral systems to differentiate between host and viral DNA and RNA.[24]

Non-mammalian types

[edit]

Avian type I IFNs have been characterized and preliminarily assigned to subtypes (IFN I, IFN II, and IFN III), but their classification into subtypes should await a more extensive characterization of avian genomes.[citation needed]

Functional lizard type I IFNs can be found in lizard genome databases.[citation needed]

Turtle type I IFNs have been purified (references from 1970s needed). They resemble mammalian homologs.

The existence of amphibian type I IFNs have been inferred by the discovery of the genes encoding their receptor chains. They have not yet been purified, or their genes cloned.

Piscine (bony fish) type I IFN has been cloned first in zebrafish.[25][26] and then in many other teleost species including salmon and mandarin fish.[27][28] With few exceptions, and in stark contrast to avian and especially mammalian IFNs, they are present as single genes (multiple genes are however seen in polyploid fish genomes, possibly arising from whole-genome duplication). Unlike amniote IFN genes, piscine type I IFN genes contain introns, in similar positions as do their orthologs, certain interleukins. Despite this important difference, based on their 3-D structure these piscine IFNs have been assigned as Type I IFNs.[29] While in mammalian species all Type I IFNs bind to a single receptor complex, the different groups of piscine type I IFNs bind to different receptor complexes.[30] Until now several type I IFNs (IFNa, b, c, d, e, f and h) has been identified in teleost fish with as low as only one subtype in green pufferfish and as many as six subtypes in salmon with an addition of recently identified novel subtype, IFNh in mandarin fish.[27][28]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Interferon type I

View on Grokipedia
from Grokipedia
Type I interferons (IFNs) constitute a family of cytokines that serve as key mediators of the innate immune response, primarily exerting antiviral, antiproliferative, and immunomodulatory effects by inducing an intracellular antiviral state in target cells. First discovered in through observations of viral interference in chick cells by Alick Isaacs and Jean Lindenmann, these proteins are produced rapidly by a wide array of cell types, including leukocytes, fibroblasts, and epithelial cells, in response to pathogen-associated molecular patterns detected by receptors such as Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs). In humans, the type I IFN family comprises 13 functional IFN-α subtypes, a single IFN-β, and additional members including IFN-ε, IFN-κ, and IFN-ω; the IFN-α subtypes share 75–99% sequence identity among themselves, while other type I IFNs show lower homology (∼30–60%) to IFN-α, all encoded by genes clustered on chromosome 9p21-22. Upon secretion, type I IFNs bind to a shared heterodimeric receptor complex, IFNAR, composed of IFNAR1 and IFNAR2 subunits, which is ubiquitously expressed on nucleated cells. This binding triggers the Janus kinase-signal transducer and activator of transcription (, where JAK1 and TYK2 phosphorylate and STAT2, leading to the formation of the interferon-stimulated gene factor 3 (ISGF3) complex that translocates to the nucleus and induces the expression of hundreds of interferon-stimulated genes (ISGs). These ISGs encode proteins that inhibit , promote in infected cells, enhance , and modulate the activity of immune cells such as natural killer (NK) cells, dendritic cells, and T lymphocytes. Beyond antiviral defense, type I IFNs also regulate adaptive immunity by promoting T cell differentiation, B cell class switching, and production, while influencing cross-talk between innate and adaptive arms of the . The production pathways of type I IFNs exhibit remarkable diversity, reflecting the need for rapid and context-specific responses to infections. Plasmacytoid dendritic cells (pDCs) are the predominant producers during systemic viral infections, secreting high levels of IFN-α via TLR7/9-MyD88-IRF7 signaling, whereas conventional dendritic cells, macrophages, and epithelial cells contribute IFN-β through RLR-MAVS-IRF3 pathways in response to cytosolic viral RNA or DNA. However, dysregulated type I IFN signaling can contribute to immunopathology, as seen in autoimmune diseases where chronic elevation of IFN-α—such as in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and dermatomyositis—correlates with disease severity and drives inflammation through excessive ISG expression and immune cell activation. Conversely, therapeutic recombinant IFN-β is a cornerstone treatment for relapsing-remitting multiple sclerosis, highlighting the nuanced balance of type I IFNs in health and disease.

Definition and Classification

General Characteristics

Type I interferons constitute a family of cytokines that primarily mediate antiviral defense by inducing an antiviral state in infected and neighboring cells, and they are produced by virtually all nucleated cells in response to viral infections or other stimuli. These proteins were first discovered in by Alick Isaacs and Jean Lindenmann, who observed a soluble factor produced by virus-infected chick cells that interfered with in uninfected cells. Evolutionarily, type I interferons are highly conserved across vertebrates, reflecting their fundamental role in innate immunity since the emergence of jawed vertebrates. Structurally, all type I interferons share a compact helical bundle composed of five alpha helices (A through E) connected by loops, enabling their interaction with cellular receptors. Their molecular weights typically range from 17 to 26 , corresponding to polypeptide chains of about 165-166 , with some subtypes exhibiting N-linked that influences stability, solubility, and bioactivity—such as IFN-β and IFN-ω, while most IFN-α subtypes are unglycosylated. In humans, the type I family encompasses 17 functional genes encoding 16 distinct proteins, including 13 IFN-α genes (encoding 12 unique variants: IFN-α1/13, IFN-α2, IFN-α4, IFN-α5, IFN-α6, IFN-α7, IFN-α8, IFN-α10, IFN-α14, IFN-α16, IFN-α17, IFN-α21, excluding pseudogenes), along with single genes for IFN-β, IFN-ε, IFN-κ, and IFN-ω, each encoded by intronless genes clustered on 9. These subtypes bind to a shared heterodimeric receptor complex known as IFNAR, consisting of the IFNAR1 and IFNAR2 subunits, which upon binding activates the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway to drive expression of interferon-stimulated genes. Although all type I interferons elicit broadly similar antiviral and immunomodulatory responses, subtle differences in receptor affinity and downstream signaling contribute to subtype-specific effects on , , and immune cell activation. This contrasts with type II interferon (IFN-γ) and type III interferons (IFN-λs), which utilize distinct receptors and exhibit more specialized functions in adaptive immunity.

Distinction from Other Interferon Types

Type I interferons are distinguished from other interferon types primarily through differences in their molecular classification, cellular production, receptor usage, and functional emphases, which were initially delineated based on antiviral activity assays and later refined by genomic analyses. The interferon family was first classified into type I and type II categories in the mid-20th century, with type I interferons identified for their broad antiviral effects in assays, while type II (IFN-γ) was recognized for its distinct, more stable antiviral profile and immune-modulatory properties. This persisted until 2003, when genomic screening identified type III interferons (IFN-λs), expanding the family and highlighting shared antiviral roles with type I but with unique tissue-specific expression patterns. Type II interferon consists of a single subtype, IFN-γ, which is predominantly produced by activated T cells and natural killer (NK) cells in response to immune stimuli such as interleukin-12 or during adaptive immune responses. Unlike type I interferons, IFN-γ signals through a dedicated receptor complex, IFNGR, composed of IFNGR1 and IFNGR2 subunits, which is widely expressed but particularly influential in hematopoietic cells. Its primary functions center on promoting Th1-type immune responses, activating macrophages for enhanced and , and inducing pro-inflammatory , rather than direct broad-spectrum antiviral activity. In contrast, type III interferons, including IFN-λ1 through IFN-λ4, share structural similarities with type I in their class II α-helical fold but exhibit distinct genomic organization with introns and are mainly produced by epithelial cells and a of immune cells like dendritic cells at barrier sites such as the respiratory and gastrointestinal mucosa. These interferons utilize a unique receptor heterodimer, IFNLR1 paired with IL10RB, which is selectively expressed on epithelial and some myeloid cells, limiting systemic effects compared to the ubiquitous IFNAR receptor of type I interferons. Functionally, type III interferons provide antiviral protection akin to type I but with a focus on mucosal barrier immunity, inducing interferon-stimulated genes (ISGs) in a more localized manner to control at entry points while minimizing widespread inflammation.
FeatureType I InterferonsType II Interferon (IFN-γ)Type III Interferons (IFN-λ)
Primary Producing CellsMost nucleated cells (e.g., fibroblasts, leukocytes)T cells, NK cellsEpithelial cells, dendritic cells
Receptor ComplexIFNAR1/IFNAR2 (ubiquitous)IFNGR1/IFNGR2 (broad, immune-focused)IFNLR1/IL10RB (epithelial-restricted)
Key FunctionsSystemic antiviral defense, Th1 promotion, activationMucosal antiviral barrier, localized ISG induction
Despite these distinctions, type I interferons exhibit overlaps and synergies with types II and III during infections, such as enhancing IFN-γ production from NK cells to amplify activation or cooperating with type III at mucosal sites to bolster epithelial antiviral states against pathogens like influenza virus.

Molecular Structure and Genetics

Type I interferons are compact proteins typically comprising 166–172 that fold into a characteristic α-helical consisting of five major helices labeled A through E, with helices A, B, C, and E forming a left-handed four-helix bundle that constitutes fold. This bundle motif, often referred to in structural analyses as the ABEF arrangement due to the positioning of helices A, B, E, and an extended segment akin to F in related cytokines, provides the scaffold for receptor interactions, while variable loops connecting helices A-B and D-E primarily determine subtype-specific binding affinities. The overall topology aligns with the long-chain cytokine family, featuring up-up-down-down helix packing that supports stability and functional diversity across subtypes. Structural integrity is maintained by conserved disulfide bonds; in IFN-α subtypes, these include a critical Cys1-Cys98 linkage essential for thermodynamic stability and an additional Cys29-Cys138 bond, both present in most human variants. In contrast, IFN-β features a single disulfide bridge between Cys31 and Cys141, which anchors the AB loop to the core. patterns vary among subtypes, influencing such as serum ; for instance, human IFN-β bears an N-linked glycan at Asn80, a biantennary complex-type that enhances and stability without disrupting the helical bundle. High-resolution structures illuminate these features, including the NMR-derived solution structure of IFN-α2a (PDB: 1ITF, 1.7 effective resolution, 1997), which highlights receptor-binding epitopes on the exposed faces of helices A and E and the AB loop. Similarly, the crystal structure of glycosylated human IFN-β at 2.2 resolution (PDB: 1AU1) reveals a compact, elongated with the bundle oriented along the protein's long axis. Type I interferons exhibit acidic isoelectric points (pI ≈ 6), distinguishing them from the basic pI (≈ 9.5) of type II IFN and influencing their electrostatic interactions with the shared heterodimeric receptor IFNAR.

Gene Organization and Expression

The type I interferon genes in humans are primarily clustered on the short arm of at the 9p21.3 locus, spanning approximately 400 kb and comprising 13 functional IFN-α genes, one IFN-β gene, and genes encoding IFN-ε and IFN-ω, interspersed with multiple pseudogenes. The IFN-κ gene is located nearby at 9p21.2. This reflects evolutionary duplication events that expanded the IFN-α subfamily, enabling diverse responses to pathogens. Approximately 10 non-functional IFN-α pseudogenes, along with several IFN-ω pseudogenes (such as IFNWP2, IFNWP4, IFNWP5, and others), serve as evolutionary relics within the cluster, contributing to the total of over 20 IFN-related loci but limiting the production of functional proteins to the specified subtypes. Transcriptional regulation of type I IFN genes is governed by specific promoter elements that facilitate both viral induction and autoregulation. The promoters, particularly of the IFN-β gene, contain positive regulatory domains (PRDs), including PRDI, PRDII, PRDIII, and PRDIV, which bind transcription factors such as /7, , and HMG-I/Y to drive rapid expression in response to viral infection. Additionally, interferon-stimulated response elements (ISREs) within these promoters enable loops, where type I IFNs bind their receptor to activate /2 and IRF9, forming ISGF3 that binds ISREs to amplify further IFN production. In terms of expression patterns, type I IFN genes are transcribed at constitutively low basal levels in most cells, reflecting a state of immune preparedness, but undergo massive upregulation—often by over 1,000-fold—following pathogen recognition through receptors. This inducible expression is tightly controlled to prevent chronic inflammation, with the IFN-β gene often serving as the primary responder to initiate the cascade. Across species, variations exist; for instance, mice possess a more contracted cluster on , with 14 functional IFN-α genes, one IFN-β, one IFN-ε, one IFN-κ, and one IFN-ω, exhibiting similar but subtype-specific expression dynamics.

Production and Regulation

Cellular Sources

Type I interferons are primarily produced by plasmacytoid dendritic cells (pDCs), which serve as the major source of IFN-α during viral infections and other immune challenges. These specialized immune cells are equipped with high constitutive levels of interferon regulatory factor 7 (IRF7), enabling rapid and robust secretion of type I IFNs upon recognition of viral nucleic acids via 7 and 9. pDCs can produce up to 1000 times more IFN-α than other cell types, releasing large quantities (e.g., up to 10 pg per cell) within hours of activation. In addition to pDCs, various non-hematopoietic and hematopoietic cells contribute to type I IFN production, with IFN-β often predominating. Fibroblasts, macrophages, and epithelial cells are key producers in tissue-specific contexts, such as during mucosal or skin infections, where they respond to cytosolic sensors like RIG-I-like receptors to limit viral spread locally. For instance, alveolar macrophages generate substantial IFN-β in the lungs against respiratory viruses, while epithelial cells in the gut or airways mount IFN responses to pathogens like or . Tissue-specific expression patterns further diversify type I IFN sources. In the liver, hepatocytes express and produce IFN-ε, contributing to baseline antiviral readiness in this organ. In ruminants, cells of the reproductive tract secrete IFN-τ during early to support maternal recognition of the and maintain function. Under basal conditions, most cells exhibit low constitutive production of type I IFNs to maintain immune , with pDCs uniquely poised for swift amplification upon induction. However, B cells have been shown to contribute to type I IFN production in contexts such as infections and , potentially exacerbating disease through dysregulated responses in the latter.

Induction Pathways

Type I interferons are induced primarily through pattern recognition receptors (PRRs) that detect viral nucleic acids, triggering signaling cascades that culminate in the transcription of IFN-α and IFN-β genes. These pathways ensure rapid activation of innate immunity upon pathogen detection, with key sensors including endosomal Toll-like receptors (TLRs) and cytosolic sensors. Endosomal TLRs play a pivotal role in IFN induction, particularly in professional antigen-presenting cells like plasmacytoid dendritic cells (pDCs). TLR3 recognizes double-stranded RNA (dsRNA) in endosomes, recruiting the adaptor TRIF to activate TBK1 and IRF3/7, leading to IFN-β transcription. In contrast, TLR7 and TLR9 detect single-stranded RNA and unmethylated CpG DNA, respectively, via the MyD88 adaptor, which promotes IRF7 activation and selective IFN-α production. These pathways are essential for responses to RNA and DNA viruses, respectively. Cytosolic PRRs provide a complementary sensing mechanism for intermediates. RIG-I and , members of the (RLR) family, recognize distinct viral structures: short 5'-triphosphorylated dsRNA for RIG-I and long dsRNA for . Upon binding, these sensors interact with the adaptor MAVS on mitochondria, initiating a cascade involving TBK1 and IKKε that phosphorylates and nuclear translocates and IRF7, driving IFN-β and IFN-α expression. This pathway is critical for detecting cytosolic viral from diverse pathogens. DNA sensing via the cGAS-STING pathway has gained prominence for its roles in antiviral defense and antitumor immunity. Cytosolic DNA activates cyclic GMP-AMP synthase (cGAS), which synthesizes the second messenger 2'3'-cGAMP. This binds and activates STING on the endoplasmic reticulum, recruiting TBK1 to phosphorylate , resulting in IFN-β transcription. Recent 2024 reviews highlight cGAS-STING's involvement in chronic viral infections and cancer, where it bridges innate sensing to adaptive responses. While PRR activation directly induces IFN production, the interferons themselves amplify the response through autocrine and via the type I interferon receptor (IFNAR). IFN-α/β binds the heterodimeric IFNAR complex (IFNAR1/IFNAR2), recruiting and activating Janus kinases JAK1 and TYK2. These phosphorylate and STAT2, which heterodimerize and associate with IRF9 to form the ISGF3 complex. ISGF3 translocates to the nucleus and binds interferon-stimulated response elements (ISREs) to transcribe IFN-stimulated genes (ISGs), including additional IFN genes for sustained production. This feedback loop is depicted in the simplified signaling equation: IFN→IFNAR→(JAK1/TYK2)→p-STAT1/STAT2→IRF9→Type I IFN [gene](/page/Gene) transcription\text{IFN} \to \text{IFNAR} \to (\text{JAK1/TYK2}) \to \text{p-STAT1/STAT2} \to \text{IRF9} \to \text{Type I IFN [gene](/page/Gene) transcription} To prevent excessive , negative regulators fine-tune these pathways. SOCS1, induced by IFN signaling, inhibits JAK1 and TYK2 activity, attenuating downstream STAT and IFN amplification. USP18 specifically destabilizes IFNAR2 and blocks JAK activation, acting as a potent brake on type I IFN responses. Dysregulation of these regulators can lead to hyper- or hypo-responsiveness. Recent advances underscore the therapeutic potential of modulating induction pathways. STING agonists, such as ulevostinag, are under evaluation in 2025 phase I/II clinical trials for cancers like , where they enhance IFN production and antitumor immunity when combined with inhibitors. Additionally, 2023 studies revealed that neutralizing autoantibodies against type I IFNs in some patients impair IFN signaling, indirectly disrupting induction feedback loops and contributing to severe disease outcomes.

Biological Functions

Antiviral Mechanisms

Type I interferons (IFNs) establish an antiviral state primarily by binding to the IFNAR receptor, activating the , which leads to the transcription of hundreds of interferon-stimulated genes (ISGs). These ISGs, numbering over 300, encode proteins that directly inhibit various stages of the cycle, including entry, transcription, translation, and assembly. Key examples include R (PKR), 2'-5'-oligoadenylate synthetase (OAS)/RNase L, and Mx proteins, which collectively disrupt viral processes without broadly harming host cells. PKR detects double-stranded viral and autophosphorylates, leading to phosphorylation of 2α (eIF2α), which blocks cap-dependent of viral mRNAs and halts protein synthesis essential for replication. Similarly, OAS senses viral to synthesize 2'-5'-linked oligoadenylates, activating latent RNase L to cleave single-stranded viral and host RNAs, thereby degrading viral genomes and transcripts. Mx proteins, dynamin-like GTPases, interfere with viral nucleocapsid trafficking; for instance, MxA traps influenza A virus nucleoproteins in the , preventing nuclear import required for replication. The antiviral response initiates rapidly, within hours of IFN exposure, as ISG expression peaks early and sustains through autocrine (on producing cells) and paracrine (on neighboring cells) signaling, amplifying protection across tissues. In (HBV) and (HSV) infections, type I IFNs induce STAT1-dependent ISGs that suppress replication; for HBV, this involves ISGs like APOBEC3A/G restricting cccDNA formation, while for HSV, ISGs such as viperin restrict by binding to D and promoting IFN-β production. A 2024 review highlights the role of ISG IFITM3, induced by type I IFNs, in limiting entry by altering levels in endosomal membranes, thereby impeding spike-mediated fusion. As of 2025, studies have further elucidated the role of ISG OAS1 in restricting variants through enhanced RNase L-mediated viral RNA degradation.

Immunomodulatory and Antiproliferative Effects

Type I interferons exert profound immunomodulatory effects by promoting the maturation of dendritic cells (DCs), which enhances their ability to present antigens and activate adaptive immune responses. Exposure to type I IFNs induces phenotypic maturation in DCs, upregulating co-stimulatory molecules and expression while allowing continued , thereby optimizing T cell priming without fully shutting down endocytic pathways. This maturation process is crucial for initiating robust immunity, as demonstrated in models where systemic type I IFN responses are required for DCs to induce + Th1 differentiation. Type I IFNs also directly activate natural killer (NK) cells and T cells, enhancing their cytotoxic functions and proliferation. They promote NK cell expansion, survival, and IFN-γ production during viral infections by signaling through the IFNAR receptor on these cells, leading to increased granzyme and perforin expression. Similarly, type I IFNs act on CD8+ T cells to boost clonal expansion and cytotoxicity; for instance, IFN-α stimulation can increase CD8+ T cell-mediated killing by 2- to 5-fold in cytotoxicity assays, as observed with specific subtypes like IFN-α4 and IFN-α6. These effects contribute to a Th1-biased immune response, where type I IFNs favor IFN-γ-producing T helper cells over other subsets. Conversely, type I IFNs inhibit Th17 differentiation and IL-17 production, suppressing pro-inflammatory pathways that drive certain autoimmune conditions through mechanisms involving reduced IL-23 signaling and enhanced Th1 skewing. In terms of antiproliferative effects, type I IFNs induce cell cycle arrest primarily by upregulating cyclin-dependent kinase inhibitors such as p21 and p27, which halt progression at the G0/G1 phase in proliferating cells like tumor or virus-infected cells. They also trigger apoptosis via upregulation of death ligands including TRAIL and FasL, as well as their receptors, promoting programmed cell death in susceptible targets. These actions are mediated through STAT1-dependent transcriptional changes following IFNAR engagement. Type I IFNs further enhance cross-talk in immune responses by increasing expression on target cells, thereby improving and recognition by cytotoxic T cells and NK cells. However, chronic exposure to type I IFNs, as seen in persistent infections like , can lead to T cell exhaustion by sustaining and impairing effector functions, highlighting a context-dependent shift from activation to dysfunction. Beyond direct immune modulation, type I IFNs inhibit through induction of like IP-10 (), which blocks endothelial and migration in response to pro-angiogenic factors such as VEGF and bFGF. They also modulate , where subtypes like IFN-κ are essential for coordinating inflammatory resolution and tissue repair, with deficiencies linked to impaired closure in diabetic models.

Mammalian Subtypes

IFN-α and IFN-β

In humans, the IFN-α subtype is encoded by 13 functional genes clustered on , producing proteins that share 70-80% sequence homology. These cytokines are primarily produced by leukocytes, such as plasmacytoid dendritic cells and monocytes, in response to viral infections and other stimuli. Among the IFN-α variants, subtypes α2a and α2b are the most commonly used in therapeutic applications due to their well-characterized antiviral and immunomodulatory properties. In contrast, IFN-β is encoded by a single gene on and is predominantly secreted by fibroblasts and epithelial cells upon recognition. This subtype often demonstrates higher potency in certain antiviral assays, such as those measuring protection against encephalomyocarditis (EMCV) in cell cultures, where it can exhibit 2- to 10-fold greater activity compared to IFN-α on a molar basis. Both IFN-α and IFN-β bind to the shared heterodimeric receptor IFNAR, composed of IFNAR1 and IFNAR2 subunits, to initiate downstream signaling. Key differences between IFN-α and IFN-β include structural modifications affecting and immune responses. IFN-β is naturally glycosylated at 80, which contributes to a longer plasma (approximately 5-6 hours versus 2-3 hours for non-glycosylated IFN-α) and reduced clearance. Conversely, IFN-α tends to be more immunogenic, potentially eliciting neutralizing antibodies during prolonged therapeutic use due to its lack of in recombinant forms. Clinically, pegylated formulations of IFN-β1a, which extend its further through conjugation, were approved in 2014 for treating relapsing-remitting . Recent studies have also linked autoantibodies against IFN-α to severe outcomes, with neutralizing antibodies detected in approximately 10% of critically ill patients in 2023 analyses.

Other Subtypes (IFN-ε, -κ, -ω, -τ, -ν, -ζ, -δ)

In addition to the principal IFN-α and IFN-β subtypes, type I interferons encompass several specialized variants with restricted expression patterns and distinct physiological roles, primarily in mammals. These include IFN-ε, IFN-κ, and IFN-ω in humans and other placental mammals, as well as species-specific forms such as IFN-τ in ruminants, IFN-δ in pigs, and IFN-ζ in mice. These subtypes share the common type I IFN receptor (IFNAR) but exhibit unique induction mechanisms, tissue , and functions beyond broad antiviral activity, often contributing to mucosal defense, , or tissue homeostasis. IFN-ε is constitutively expressed in the epithelial cells of the reproductive tract, where it provides baseline mucosal antiviral without strong induction by viral stimuli. This hormone-regulated subtype, particularly responsive to , plays a critical role in defending against sexually transmitted infections such as , , and by establishing an antiviral state in epithelial barriers and modulating local immune responses, including activity in the . Unlike IFN-α or IFN-β, IFN-ε shows lower potency in systemic antiviral assays but is highly effective for reproductive tract immunity and may suppress tumorigenesis in estrogen-sensitive tissues. IFN-κ is predominantly produced by in the , where it maintains epidermal and a basal interferon response essential for barrier integrity. This subtype is induced by ultraviolet radiation and contributes to antiviral defense in , while also regulating secretion during ; its expression is notably reduced in diabetic , impairing repair processes. IFN-κ supports immune by positively feeding back on its own production and enhancing resistance to pathogens like type 1, distinguishing it from more ubiquitously induced type I IFNs. IFN-ω exhibits broad but low-level expression across leukocytes and other cells in humans, with potent antiviral and antiproliferative activities comparable to IFN-α subtypes, though its receptor affinity is moderately lower, leading to quantitative differences in signaling strength. This subtype triggers robust expression upon inflammatory stimulation and has shown therapeutic promise in veterinary applications, such as feline viral infections; in humans, reviews highlight its potential for treating conditions unresponsive to IFN-α, including certain cases, due to similar antitumor and immunomodulatory effects. Among species-specific subtypes, IFN-τ is unique to ruminants like sheep and , where it is secreted by trophectoderm cells during early pregnancy to signal maternal recognition and maintain the . By inhibiting uterine expression, IFN-τ prevents luteolysis and supports implantation without the strong systemic inflammatory effects of other type I IFNs, underscoring its specialized role in reproductive physiology. IFN-δ, identified in pigs, represents the smallest known type I IFN mature protein (149 ) and is enriched in residues, contributing to its stability and potent antiviral activity against porcine viruses like reproductive and respiratory virus. This porcine-specific subtype displays diverse expression profiles across immune cells and exhibits broad-spectrum inhibition of , highlighting evolutionary adaptations in immunity. In mice, IFN-ζ (also known as limitin) is produced by stromal cells, including osteoblasts, and functions in homeostasis by inhibiting precursor generation and supporting antiviral responses in specific tissues like the liver. This subtype shares type I IFN signaling but has restricted expression, aiding in localized immune regulation. These variants illustrate the diversification of type I IFNs across mammalian species for niche protective roles.

Role in Diseases

In Viral Infections

Type I interferons play a crucial protective role in the early control of both RNA and DNA viral infections by rapidly inducing the expression of interferon-stimulated genes (ISGs), which establish an antiviral state in infected and neighboring cells. For instance, in hepatitis C virus (HCV) infection, type I IFNs promote viral clearance through ISG-mediated inhibition of viral replication and enhancement of adaptive immune responses. Similarly, type I IFNs effectively restrict the spread of viruses such as West Nile virus (WNV) in human cells, with IFN-β demonstrating particularly potent antiviral activity by upregulating ISGs that interfere with viral entry and assembly. This early IFN response is essential for limiting initial viral dissemination at mucosal sites and preventing systemic infection. However, excessive or sustained type I IFN signaling in chronic viral infections can contribute to pathogenic outcomes, including immune exhaustion. In chronic infection, persistent type I IFN secretion drives metabolic reprogramming in T cells, leading to exhaustion characterized by reduced effector functions and impaired antiviral immunity. This chronic IFN exposure promotes and terminal differentiation of + T cells, exacerbating disease progression and limiting responses to blockade. Neutralizing autoantibodies against IFN-α are associated with life-threatening viral infections, particularly in cases of severe , where they are detected in approximately 10-20% of critically ill patients. These autoantibodies inhibit type I IFN signaling, impairing the innate antiviral response and increasing susceptibility to uncontrolled and . Beyond , such autoantibodies underlie severe viral pneumonias from other pathogens, highlighting their role in inborn errors of type I IFN immunity. Aging is linked to a declining type I IFN response, which heightens susceptibility to viral infections through dysregulation of pathways like STING. Chronic STING pathway activation in aged immune cells leads to diminished IFN production and responsiveness, resulting in higher viral loads during infections such as (IAV). This age-related impairment in IFN-mediated antiviral defense contributes to poorer outcomes in older individuals. In viral models mimicking (MS)-like demyelination, such as Theiler's murine encephalomyelitis virus (TMEV) infection, IFN-β exerts protective effects by delaying disease progression and reducing demyelination severity. IFN-β deficiency in these models accelerates fatal , underscoring its role in modulating and preserving integrity during neurotropic viral infections.

In Cancer

Type I interferons (IFNs) exhibit a dual role in cancer, acting as tumor suppressors by enhancing antitumor immunity while also promoting tumor progression in chronic settings through immune exhaustion mechanisms. In their suppressive capacity, type I IFNs promote CD8+ T cell infiltration into tumors by activating dendritic cells and upregulating MHC class I expression on tumor cells, thereby facilitating antigen presentation and cytotoxic T cell recognition. This antiproliferative effect contributes to direct inhibition of tumor cell growth. Deletions in the type I IFN gene cluster on chromosome 9p21 occur in 7-31% of tumors across various cancers, including melanoma, where such losses correlate with poor prognosis and reduced immune gene expression. In chronic exposure scenarios, type I IFNs can foster tumor promotion by inducing T cell exhaustion; sustained signaling upregulates on tumor and immune cells, suppressing cytotoxic responses and enabling immune evasion.01518-2) Within the tumor microenvironment (TME), type I IFNs modulate immune cell functions, enhancing natural killer (NK) cell activation and cytotoxicity while polarizing tumor-associated macrophages (TAMs) toward an antitumor M1 phenotype, though context-dependent effects can also support pro-tumor activities. A 2024 review highlights how IFN signaling in myeloid and lymphoid cells shapes TME dynamics, influencing TAM recruitment and NK cell-mediated tumor control. Copy number variations in the IFN show amplifications are rare, whereas deletions are common in ovarian and cancers, often attenuating IFN responses and contributing to immune escape. The cGAS-STING-type I IFN axis plays a critical role in responses by sensing cytosolic DNA in tumors, triggering IFN production that amplifies antitumor immunity and predicts efficacy of checkpoint inhibitors.

In Autoimmune and Inflammatory Conditions

Type I interferons (IFNs) play a central role in the of systemic lupus erythematosus (SLE), where an elevated IFN signature—characterized by overexpression of IFN-stimulated genes (ISGs)—is observed in 50–80% of patients. This signature correlates with disease activity and contributes to immune dysregulation by lowering the activation threshold of , promoting their survival, differentiation, and production. In a 2023 review, type I IFNs were highlighted as key drivers of hyperactivity in SLE, sustaining chronic through enhanced plasmablast expansion and autoantigen presentation. In other autoimmune conditions, type I IFNs contribute to localized tissue pathology. In (RA), IFN-α is produced by plasmacytoid dendritic cells in the synovium, amplifying joint inflammation and correlating with disease severity in subsets of patients. Systemic sclerosis (SSc) features an early IFN signature that precedes , with ISGs promoting activation and deposition, thereby exacerbating skin and organ . Similarly, in Sjögren's syndrome, type I IFNs drive glandular inflammation by inducing epithelial cell and production, leading to lymphocytic infiltration and salivary dysfunction. Key mechanisms underlying these effects include self-sustaining feedback loops driven by plasmablast-derived IFN-α, which promotes further activation and secretion in autoimmune settings. Hyperactivation of pathway, as seen in conditions like Aicardi-Goutières syndrome, triggers excessive type I IFN production, perpetuating sterile inflammation through cytosolic DNA sensing. As of November 2025, type I IFNs have been shown to exert dual, state-dependent effects in , supporting intestinal epithelial and under normal conditions while potentially contributing to exacerbated and impaired repair during active disease flares.

Therapeutic Applications

Antiviral Therapies

Type I interferons have been pivotal in antiviral therapies for several viral infections, particularly (HCV) and (HBV), where they induce an antiviral state in infected cells by upregulating interferon-stimulated genes that inhibit . Prior to 2011, the standard treatment for chronic HCV infection was a combination of interferon-alpha (IFN-α) and , approved by the FDA in 1998, which achieved sustained virologic response rates of up to 50% in 1 patients when using pegylated formulations. With the advent of direct-acting antivirals (DAAs), IFN-α-based regimens have largely been supplanted due to higher efficacy and tolerability of DAAs alone, though pegylated IFN-α remains an adjunct in select cases, such as quad therapy for prior null responders or patients with multi-DAA resistant strains. For chronic HBV, pegylated IFN-α2a (peg-IFN-α2a) is an approved therapy, particularly for HBeAg-positive patients, where it promotes HBeAg seroconversion in approximately 30% of cases at 48 weeks post-treatment by enhancing immune-mediated viral clearance. This seroconversion rate reflects the drug's ability to restore immune control, though it is less effective in HBeAg-negative disease. In COVID-19, clinical trials have yielded mixed results for type I interferons; subcutaneous or intravenous IFN-β1b reduced 28-day mortality and hospitalization duration in some hospitalized patients, but efficacy varies by timing and patient factors. Inhaled formulations, such as IFN-β1a (SNG001), showed safety and a trend toward reduced hospitalization in a 2023 phase II trial, though the decrease was not statistically significant.00427-3/fulltext) Autoantibodies against type I IFNs, present in about 10% of severe cases, predict non-response and increased pneumonia risk, underscoring the need for IFN status screening. As an adjunct in HIV management, IFN-α suppresses latent viral reservoirs by activating interferon-stimulated genes in infected cells, potentially aiding "shock and kill" strategies to reduce proviral DNA loads. However, prolonged use risks T-cell exhaustion, limiting its clinical adoption, as noted in recent reviews of chronic HIV immune dynamics. Emerging applications focus on type III interferon-lambda (IFN-λ), which offers targeted antiviral effects with minimal due to its epithelial-specific receptor expression. Intranasal IFN-λ delivery effectively inhibits virus replication in the upper airways, preventing spread to the lungs in preclinical models, and limits side effects compared to type I IFNs. Clinical translation of nasal IFN-λ is underway for respiratory viruses like , leveraging its localized action to enhance mucosal immunity.

Cancer Treatments

Type I interferons, particularly IFN-α, were among the first biologic agents approved for , demonstrating significant clinical activity in hematologic malignancies. In 1986, the U.S. approved recombinant IFN-α for the treatment of , based on phase II trials showing overall response rates of 80-90%, including normalization of blood counts and reduction in hairy cells in the . This approval marked a milestone in interferon-based , with durable responses observed in many patients, though subsequent purine analogs like have largely supplanted it as first-line therapy. For solid tumors, high-dose IFN-α2b was approved in 1995 as following surgical resection in patients with stage IIB-III , improving relapse-free survival by enhancing antitumor immune responses, albeit with substantial toxicity limiting its widespread use. Contemporary strategies leverage type I interferons in combination regimens to potentiate inhibitors. For instance, trials combining nivolumab with IFN-α2b have explored enhanced T-cell infiltration and activation in advanced solid tumors, such as fibrolamellar , where the interferon boosts and synergizes with PD-1 blockade to overcome immunosuppressive microenvironments. Preclinical and early-phase data indicate that this pairing increases CD8+ T-cell recruitment into tumors, potentially improving response rates in interferon-resistant settings. STING agonists represent an indirect approach to harness type I interferon induction for cancer therapy, often combined with checkpoint inhibitors for synergistic effects. Agents like DMXAA (in preclinical mouse models) and ADU-S100 (in human trials) activate the STING pathway, leading to robust type I IFN production that promotes dendritic cell maturation and T-cell priming, enhancing the efficacy of PD-1/PD-L1 blockade in preclinical tumor models. Clinical studies have shown that intratumoral ADU-S100 administration induces IFN-driven inflammation, correlating with increased CD8+ T-cell expansion and tumor regression when paired with checkpoint therapy. Despite these advances, resistance to type I interferon therapies poses significant challenges in . Mutations or downregulation of the type I receptor (IFNAR) impair signaling, leading to reduced antiproliferative effects and immune activation in tumors like , where IFNAR1 loss correlates with therapy failure. Additionally, copy number losses in the on 9p21 are associated with poor and diminished response to IFN-based treatments, as they attenuate intrinsic tumor cell sensitivity and immune surveillance. Emerging approaches in 2025 integrate type I interferons with chimeric antigen receptor (CAR) T-cell therapy to address solid tumor barriers. Preclinical models demonstrate that CAR-T cells engineered to secrete IFN-β enhance local type I IFN signaling, improving T-cell persistence, tumor infiltration, and antitumor efficacy against immunosuppressive solid malignancies like glioblastoma. This "armored" strategy counters the tumor microenvironment's inhibitory effects, with ongoing trials evaluating its safety and response rates in refractory solid tumors.

Autoimmune Disease Management

In (MS), recombinant (IFN-β1b, marketed as Betaseron) was the first disease-modifying therapy approved by the FDA in 1993 for relapsing-remitting forms of the disease. Clinical trials demonstrated that subcutaneous IFN-β1b at 250 μg every other day reduces the annualized relapse rate by approximately 30% compared to placebo, alongside an 80% reduction in new or enlarging (MRI) lesions. This therapeutic benefit arises from IFN-β1b's immunomodulatory effects, including the upregulation of anti-inflammatory interferon-stimulated genes (ISGs) such as those promoting regulatory T-cell expansion and suppressing proinflammatory production, while downregulating matrix metalloproteinases and enhancing blood-brain barrier integrity. For systemic lupus erythematosus (SLE), (Saphnelo), a fully targeting the type I interferon receptor (IFNAR), received FDA approval in 2021 for adults with moderate-to-severe disease despite standard therapy. By blocking IFNAR1 and IFNAR2 subunits, neutralizes signaling from all type I IFNs, thereby suppressing the elevated type I IFN gene signature prevalent in up to 80% of SLE patients, which correlates with disease activity across cutaneous, musculoskeletal, and systemic domains. In the TULIP-2 phase III trial, achieved a BICLA response rate of 47.8% at week 52 compared to 31.5% for (difference of 16.3 percentage points), with particular efficacy in reducing manifestations and use in IFN signature-high patients. Janus kinase (JAK) inhibitors, such as , offer an alternative by targeting downstream signaling of the type I IFN pathway in (RA) and systemic sclerosis (SSc). Approved for RA in 2018, selectively inhibits JAK1 and JAK2, thereby attenuating IFNAR-mediated activation of /STAT2 transcription factors and reducing ISG expression, proinflammatory release, and activation. In RA, it achieves American College of Rheumatology 20% improvement criteria in 70% of patients refractory to TNF inhibitors, while emerging data in SSc indicate improvements in skin fibrosis and via suppression of type I IFN-driven inflammation. Despite these advances, challenges persist in type I IFN modulation for autoimmune , including paradoxical flares where unexpectedly exacerbates , potentially due to unbalanced immune shifts or enhanced type I IFN production in response to pathway . A 2025 review highlights the therapeutic potential of targeting type III IFN-λ in Sjögren's syndrome, where elevated IFN-λ contributes to glandular and B-cell hyperactivity, suggesting anti-IFN-λ agents could address unmet needs beyond type I IFN inhibitors. Monitoring type I IFN signatures via peripheral blood profiles aids in predicting therapeutic response; for instance, high baseline IFN signatures in SLE often identify non-responders to conventional immunosuppressants like , guiding stratification toward IFN-targeted therapies such as .

Adverse Effects and Dysregulation

Side Effects of Therapy

Type I interferon therapies, primarily interferon-alpha and interferon-beta formulations, are associated with a range of acute and chronic side effects due to their potent immunomodulatory actions. These adverse effects are iatrogenic, arising from exogenous administration in treatments for viral infections, cancers, and autoimmune conditions, and their severity often correlates with dosage and duration. While many symptoms are manageable, they can lead to treatment discontinuation in a significant proportion of patients. The most prevalent acute side effects are flu-like symptoms, affecting approximately 80% of patients, manifesting as fever, chills, , , and , typically occurring shortly after injection. These symptoms are mediated by release induced by signaling, which activates inflammatory pathways. with nonsteroidal drugs can mitigate their intensity, and incidence tends to decrease over time with continued therapy. Hematologic toxicities are common and dose-dependent, including and resulting from . occurs in up to 20-30% of patients on standard interferon-alpha regimens, often requiring dose adjustments or supportive care like platelet transfusions in severe cases, while affects 10-25% and is exacerbated when combined with . These effects stem from interferon's inhibition of hematopoiesis, and monitoring of blood counts is standard during . Neuropsychiatric adverse effects represent a major concern, with depression developing in 20-30% of patients, often within the first 2-3 months of treatment, and linked to modulation of serotonin pathways via increased activity that depletes , a serotonin precursor. occurs in 5-10% of cases, particularly in those with preexisting vulnerabilities, prompting routine psychiatric screening and prophylactic antidepressants in high-risk individuals. These symptoms can persist post-therapy in some cases. Long-term toxicities include autoimmune thyroiditis, with or emerging in 5-15% of patients after prolonged exposure, driven by interferon's enhancement of thyroid autoimmunity. Cardiotoxicity, such as or arrhythmias, is rarer (affecting <1-2%) but can be severe, involving direct myocardial or ischemia, and typically resolves upon discontinuation. Pegylated formulations, which extend and reduce injection frequency, lower the overall incidence of these side effects by 20-50% compared to standard interferons, though they do not eliminate the risks entirely. In the context of COVID-19 trials, a 2023 meta-analysis of randomized controlled trials indicated that in severe cases failed to reduce 28-day mortality and was associated with higher odds of adverse outcomes, potentially due to exacerbation of in advanced disease stages.

Pathological Overproduction

Pathological overproduction of type I interferons (IFNs) can arise through non-genetic mechanisms, leading to sustained signaling that disrupts immune and contributes to tissue pathology. In chronic viral infections such as and (HCV), persistent antigen exposure drives continuous low-level production of type I IFNs, which paradoxically promotes T-cell exhaustion rather than effective viral clearance. This exhaustion is marked by upregulated inhibitory receptors like PD-1 on CD8+ T cells, impairing their proliferative and cytotoxic functions, as observed in longitudinal studies of infected patients. Environmental triggers, including (UV) radiation and viral infections, can exacerbate type I IFN overproduction in susceptible individuals, particularly those with autoimmune predispositions like systemic (SLE). UV exposure activates the cGAS-STING pathway in , inducing a systemic type I IFN signature that correlates with disease flares, including increased production and skin inflammation. Similarly, viral infections stimulate plasmacytoid dendritic cells to release type I IFNs via signaling, amplifying activity through enhanced B-cell activation and immune complex deposition. With advancing age, dysregulation of type I IFN signaling often results from declined negative , leading to elevated baseline IFN levels and contributing to chronic low-grade inflammation or "inflammaging." This shift is linked to broader immune senescence, where persistent IFN exposure impairs adaptive responses and promotes pro-inflammatory states in tissues like the and periphery. Emerging research highlights underexplored repressors of type I IFN production, such as interferon regulatory factor 2 (IRF2), which competes with activators like IRF1 for promoter binding sites on IFN genes. A 2024 review emphasizes IRF2's role in fine-tuning IFN responses, noting that its insufficient activity in non-genetic contexts—due to epigenetic silencing or post-translational modifications—allows unchecked IFN induction during stress or infection. This regulatory gap underscores the need for targeted therapies to restore repressor function and mitigate pathological excess. The downstream consequences of such overproduction include vascular damage and independent of genetic mutations. Elevated type I IFNs promote by upregulating adhesion molecules and , fostering leukocyte infiltration and vasculitis-like lesions in conditions like SLE. In fibrotic diseases such as systemic sclerosis, sustained IFN signaling stimulates fibroblasts to produce components via increased TGF-β and profibrotic , resulting in tissue scarring without inherited defects. These effects highlight type I IFNs' dual role in repair and pathology when dysregulated.

Interferonopathies

Genetic Mechanisms

Monogenic interferonopathies arise from inherited mutations that disrupt , leading to persistent activation of innate immune sensors and chronic type I interferon production. Loss-of-function mutations in TREX1, which encodes a 3'–5' that degrades cytosolic DNA, impair the clearance of self-DNA, allowing accumulation of nucleic acids that activate the cGAS-STING pathway. Similarly, mutations in RNASEH2, part of the RNase H2 complex responsible for removing ribonucleotides from DNA, result in genomic instability and the release of immunogenic nucleic acids, further stimulating cGAS-STING-mediated interferon responses. These defects mimic viral infection signals, driving autoinflammation without external pathogens. Aicardi-Goutières syndrome (AGS), a prototypical type I interferonopathy, exemplifies this mechanism through biallelic mutations in TREX1, RNASEH2A/B/C, or related genes like SAMHD1 and ADAR1. These alterations lead to incomplete degradation of endogenous retroelements, such as retroviral-derived sequences, which are processed into double-stranded or DNA that triggers type I signatures in affected tissues. The resulting overactivity stems from failed homeostatic control of these retroelements, establishing AGS as a model for how genetic lesions in handling provoke immune dysregulation. In contrast, STING-associated vasculopathy with onset in infancy (SAVI) involves heterozygous gain-of-function mutations in STING1 (TMEM173), which encodes the STING protein central to the pathway. These mutations cause ligand-independent oligomerization and activation of STING, directly upregulating type I interferon and proinflammatory cytokines independent of upstream nucleic acid sensors. The STING pathway, briefly, serves as a critical bridge from cytosolic DNA detection to interferon induction, and its hyperactivation in SAVI underscores the pathway's role in monogenic overproduction. Recent 2025 studies have identified biallelic in USP18, leading to severe interferonopathy by compromising its regulatory function via impaired ISG15 binding. These monogenic conditions remain rare, with an estimated below 1 in 100,000 individuals, and prenatal diagnosis is feasible through elevated scores in or fetal blood.

Clinical Syndromes

Type I interferonopathies encompass a spectrum of rare genetic disorders characterized by dysregulated type I interferon signaling, leading to autoinflammatory manifestations that often mimic viral infections or autoimmune conditions. These syndromes typically present in infancy or with driven by chronic interferon overproduction. Key examples include Aicardi-Goutières syndrome (AGS), STING-associated vasculopathy with onset in infancy (SAVI), and proteasome-associated autoinflammatory syndromes such as chronic atypical neutrophilic dermatosis with and elevated temperature () and Singleton-Merten syndrome (SJ). Caused by mutations in genes involved in sensing or interferon pathway regulation, these conditions highlight the pathological consequences of unchecked interferon responses. AGS, the prototypical interferonopathy, manifests primarily with severe neurological involvement, including progressive , intracranial calcifications (particularly in the ), and , often accompanied by and developmental delay. Cutaneous features such as —cold-induced vasculitic lesions on acral areas—occur in up to 40% of cases, alongside systemic signs like , , and elevated cerebrospinal lymphocytosis. Management focuses on mitigating interferon-driven inflammation; Janus kinase (JAK) inhibitors, such as , have shown efficacy in reducing expression and improving skin lesions and neurological symptoms in select patients, allowing tapering. Early JAK inhibition may preserve neurodevelopment, though outcomes remain guarded due to irreversible brain damage in advanced cases. SAVI presents with early-onset , characterized by progressive and respiratory insufficiency, alongside affecting small vessels, leading to ulcerative skin lesions on the face, ears, nose, fingers, and toes. Inflammatory markers are elevated, with systemic features including fever, joint pain, and occasional organ involvement like . Therapeutic responses to anti-tumor factor (TNF) agents, such as , are partial, often controlling cutaneous and joint symptoms but failing to halt lung progression; JAK inhibitors like provide additional benefit by targeting downstream signaling. CANDLE and related syndromes, including SJ, arise from dysfunction impairing protein degradation and triggering innate immune activation. CANDLE features recurrent fevers, violaceous skin lesions (), progressive with partial fat loss, calcifications, , and joint contractures, often with elevated acute-phase reactants and . SJ overlaps with dental dysplasia, aortic and valvular calcifications, , and , expanding the phenotypic spectrum. Interleukin-1 (IL-1) and IL-6 blockers, such as and , offer symptomatic relief by addressing secondary storms, reducing fever and inflammation, though they do not fully normalize signatures. Recent 2024 insights have broadened the interferonopathy spectrum to encompass atypical systemic lupus erythematosus (SLE)-like presentations, with monogenic interferon dysregulation explaining interferon-high subsets previously classified as idiopathic. , a JAK1/2 inhibitor, demonstrates efficacy in refractory cases across these syndromes, normalizing interferon signatures and improving constitutional symptoms, lung function, and , as evidenced in cohort studies. varies by syndrome and intervention timing; AGS carries high morbidity with neurodevelopmental impairment in over 80% of untreated cases, while SAVI and show better stabilization with early , underscoring the need for prompt genetic diagnosis and to optimize long-term outcomes.

Non-Mammalian Interferons

In Other Vertebrates

In fish, type I interferons exhibit distinct structural features compared to those in mammals, including the presence of IFN-φ and other subtypes characterized by four-cysteine motifs that form two disulfide bonds, enabling binding to specific receptor complexes. These motifs contribute to a broader antiviral spectrum, allowing fish IFNs to combat a wider range of viral pathogens through enhanced stability and receptor interaction diversity. Unlike the intronless genes predominant in mammalian type I IFNs, fish IFN genes often contain introns, reflecting an evolutionary divergence post-teleost whole-genome duplication. Birds possess a more limited repertoire of type I interferon subtypes than mammals, with IFN-κ emerging as a dominant form that plays a key role in antiviral defense. High expression of IFN-α has been associated with enhanced resistance to viruses, as it potently induces interferon-stimulated genes that restrict viral replication in respiratory tissues. This streamlined IFN system supports efficient innate immunity tailored to avian pathogens, with fewer duplications overall compared to mammalian diversity. In amphibians and reptiles, type I interferons display hybrid characteristics, combining intronless and intron-containing gene structures that bridge evolutionary transitions between fish and higher vertebrates. For instance, harbors both forms, with 16 intronless and five intron-containing type I IFN genes, enabling adaptive responses to ranaviruses. In reptiles like the Chinese soft-shelled turtle, seven type I IFN genes have been identified. The receptor complex IFNAR, or its homologs such as CRFB in , is universally conserved across vertebrates, facilitating type I IFN signaling from to mammals. A 2023 evolutionary analysis highlights gene duplications in the IFN locus following the teleost-specific duplication, which expanded subtype diversity in ray-finned while maintaining core functional conservation in other lineages. Veterinary applications of type I IFNs extend to non-human mammals, where recombinant IFN-α is used to manage infections, improving survival rates and reducing through immunomodulatory effects. Low-dose has shown efficacy in alleviating and enhancing leukocyte counts in affected cats.

Evolutionary Aspects and

The evolutionary origins of type I interferons trace back to ancient antiviral mechanisms present in early metazoans, with key components like viperin homologs identified in cnidarians such as Nematostella vectensis. These viperin-like proteins exhibit direct antiviral activity by inhibiting , suggesting that IFN-like effector functions predated the emergence of true interferons in vertebrates. Viperin's conservation across eukaryotes, including serial innovations on its scaffold, underscores its role as a primordial defense against RNA viruses in non-bilaterian animals. In vertebrates, the type I interferon system underwent significant expansion through whole-genome duplications during early evolution. The two rounds of whole-genome duplication (2R-WGD) in ancestral vertebrates contributed to the diversification of regulatory factors (IRFs) from an initial set of precursors to the modern family of up to 10 members, enabling more sophisticated signaling. This genomic event, occurring around 500 million years ago, facilitated the evolution of type I IFNs from a class II helical ancestor shared with the interleukin-10 family, with subtypes like IFNA and IFNB emerging approximately 250 million years ago. Invertebrates lack true type I interferons, as these cytokines are vertebrate innovations, but they possess orthologous components and pathways that mimic IFN induction and antiviral responses. In Drosophila melanogaster, the Toll and Immune deficiency (Imd) pathways serve as major regulators of innate immunity, activating transcription factors like Relish (an NF-κB homolog) to induce antimicrobial peptides and antiviral genes upon microbial challenge. These pathways parallel the IRF-mediated IFN signaling in vertebrates by coordinating humoral defenses, including JAK-STAT activation that produces Vago, an IFN-like cytokine with roles in combating viruses such as invertebrate iridescent virus 6. A conserved element predating even cnidarian IFN-like systems is the (STING) pathway, with homologs identified in sponges (Porifera), the earliest diverging animal phylum. Recent analyses highlight STING's presence in sponges and choanoflagellates, where it detects cytosolic nucleic acids and triggers innate immune responses, providing a foundational mechanism for antiviral immunity that antedates vertebrate IFNs by hundreds of millions of years. This deep conservation is reviewed in 2024 literature on marine invertebrate immunity, emphasizing STING's role in sensing across basal metazoans. Functional analogs to interferons appear in cnidarians through cytokine-like molecules that orchestrate antiviral defenses, such as retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) derived from an ancestral /LGP2 precursor. In N. vectensis, these systems induce interferon-stimulated genes (ISGs) like viperin and RNase L upon viral infection, revealing ancestral complexity in non-bilaterian antiviral immunity. Studies of such invertebrate models offer critical insights into the origins of human type I IFN pathways, highlighting how primordial sensors evolved into the integrated interferon system.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC4666791/
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3572907/
  3. https://pmc.ncbi.nlm.nih.gov/articles/PMC10734085/
  4. https://pmc.ncbi.nlm.nih.gov/articles/PMC7123835/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC5332411/
  6. https://www.pnas.org/doi/10.1073/pnas.94.22.11813
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC3695685/
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC7850986/
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC3986811/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC6839410/
  11. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2020.605673/full
  12. https://pubmed.ncbi.nlm.nih.gov/9417943/
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC23607/
  14. https://pubs.acs.org/doi/10.1021/acs.jpcb.1c07090
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC2990676/
  16. https://www.genenames.org/data/genegroup/#!/group/598
  17. https://academic.oup.com/intimm/article/17/11/1367/813291
  18. https://www.nature.com/articles/nri1604
  19. https://www.nature.com/articles/nri3787
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC8072550/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC6473462/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC9642105/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC2000448/
  24. https://febs.onlinelibrary.wiley.com/doi/10.1002/1873-3468.14625
  25. https://www.sciencedirect.com/science/article/pii/S0021925820874043
  26. https://www.nature.com/articles/s41577-020-0288-3
  27. https://www.sciencedirect.com/science/article/pii/S0952791524000141
  28. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1352479/full
  29. https://www.sciencedirect.com/science/article/pii/S107476131200132X
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC7079803/
  31. https://jlb.onlinelibrary.wiley.com/doi/full/10.1002/JLB.2MIR0817-342R
  32. https://portlandpress.com/bioscirep/article/38/6/BSR20180250/98249/USP18-a-multifunctional-component-in-the
  33. https://aacrjournals.org/clincancerres/article/31/16/3400/763979/Phase-I-and-II-Clinical-Studies-of-the-STING
  34. https://www.sciencedirect.com/science/article/pii/S2589004223011616
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC3274382/
  36. https://pmc.ncbi.nlm.nih.gov/articles/PMC4313732/
  37. https://www.mdpi.com/1422-0067/20/7/1620
  38. https://www.nature.com/articles/nri2314
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC7756014/
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC7935137/
  41. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.1034968/full
  42. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.02810/full
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC11389394/
  44. https://www.nature.com/articles/s41579-025-01123-4
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC3311734/
  46. https://rupress.org/jem/article/206/7/1589/40338/Dendritic-cells-require-a-systemic-type-I
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC4749923/
  48. https://pmc.ncbi.nlm.nih.gov/articles/PMC6771563/
  49. https://www.nature.com/articles/s41467-020-16625-7
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC2907165/
  51. https://www.sciencedirect.com/science/article/pii/S0021925820470097
  52. https://aacrjournals.org/clincancerres/article/17/9/2619/12936/Direct-Effects-of-Type-I-Interferons-on-Cells-of
  53. https://pubmed.ncbi.nlm.nih.gov/40573365/
  54. https://www.sciencedirect.com/science/article/pii/S0049384818300471
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC9090246/
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC3442264/
  57. https://journals.physiology.org/doi/10.1152/physrev.00047.2024
  58. https://www.ncbi.nlm.nih.gov/books/NBK555932/
  59. https://ashpublications.org/hematology/article/2024/1/535/526195/Pegylated-interferon-the-who-why-and-how
  60. https://pubmed.ncbi.nlm.nih.gov/6183692/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC327215/
  62. https://www.pnas.org/doi/10.1073/pnas.0609001104
  63. https://jpharmsci.org/article/S0022-3549%2818%2930736-6/fulltext
  64. https://www.nature.com/articles/s41598-020-65495-y
  65. https://pmc.ncbi.nlm.nih.gov/articles/PMC7446632/
  66. https://pubmed.ncbi.nlm.nih.gov/36907547/
  67. https://www.liebertpub.com/doi/10.1089/jir.2023.0087
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC8863823/
  69. https://pmc.ncbi.nlm.nih.gov/articles/PMC10032502/
  70. https://insight.jci.org/articles/view/135407
  71. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0071320
  72. https://pubmed.ncbi.nlm.nih.gov/31734130/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC6551332/
  74. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1239598/full
  75. https://www.sciencedirect.com/science/article/abs/pii/S1567576917303351
  76. https://onlinelibrary.wiley.com/doi/10.1002/eji.70003
  77. https://rep.bioscientifica.com/view/journals/rep/154/5/REP-17-0432.xml
  78. https://pubmed.ncbi.nlm.nih.gov/40974846/
  79. https://www.sciencedirect.com/science/article/abs/pii/S0300908499800303
  80. https://pubmed.ncbi.nlm.nih.gov/20406849/
  81. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0112378
  82. https://www.dent.meikai.ac.jp/media/library/new-journals/2009_V38/1-8.pdf
  83. https://www.sciencedirect.com/science/article/pii/S1074761321004581
  84. https://rupress.org/jem/article/208/10/2005/40934/Host-type-I-IFN-signals-are-required-for-antitumor
  85. https://pmc.ncbi.nlm.nih.gov/articles/PMC8458777/
  86. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0109760
  87. https://www.nature.com/articles/s41422-019-0224-x
  88. https://pmc.ncbi.nlm.nih.gov/articles/PMC11049350/
  89. https://www.sciencedirect.com/science/article/pii/S2666379125003891
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC11972543/
  91. https://www.embopress.org/doi/10.15252/embr.201846935
  92. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.633821/full
  93. https://academic.oup.com/immunohorizons/article/4/3/140/7820494
  94. https://www.jrheum.org/content/50/9/1103
  95. https://pmc.ncbi.nlm.nih.gov/articles/PMC10787895/
  96. https://pmc.ncbi.nlm.nih.gov/articles/PMC7977624/
  97. https://www.sciencedirect.com/science/article/pii/S1568997212002649
  98. https://www.sciencedirect.com/science/article/pii/S0896841125000836
  99. https://onlinelibrary.wiley.com/doi/10.1111/sji.13314
  100. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1713424/full
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC7108252/
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC2990099/
  103. https://www.sciencedirect.com/science/article/abs/pii/S0166354214000394
  104. https://www.nature.com/articles/srep29605
  105. https://pmc.ncbi.nlm.nih.gov/articles/PMC2716864/
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC7445008/
  107. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2018.00299/full
  108. https://www.mdpi.com/1999-4915/17/2/139
  109. https://www.embopress.org/doi/10.15252/emmm.201606413
  110. https://www.sciencedirect.com/science/article/pii/S2211124722005666
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC4923076/
  112. https://www.curemelanoma.org/patient-eng/melanoma-treatment/options/interferon-intron-a-or-sylatron
  113. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1249330/full
  114. https://fibrofoundation.org/new-clinical-trial-testing-nivolumab-5-fu-and-interferon-alpha-2b-now-open/
  115. https://www.targetedonc.com/view/the-potential-of-sting-agonists-is-explored-in-cancer
  116. https://pmc.ncbi.nlm.nih.gov/articles/PMC10994474/
  117. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2018.00322/full
  118. https://insight.jci.org/articles/view/193048
  119. https://pmc.ncbi.nlm.nih.gov/articles/PMC2726074/
  120. https://jamanetwork.com/journals/jamaneurology/fullarticle/774791
  121. https://mymsaa.org/treatment/betaseron/
  122. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1161849/full
  123. https://pubmed.ncbi.nlm.nih.gov/21649449/
  124. https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/saphnelo-approved-in-the-us-for-sle.html
  125. https://ard.bmj.com/content/83/8/1018
  126. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761123Orig1s000MultidisciplineR.pdf
  127. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.932240/full
  128. https://www.sciencedirect.com/science/article/abs/pii/S1568997222001380
  129. https://pmc.ncbi.nlm.nih.gov/articles/PMC9312477/
  130. https://onlinelibrary.wiley.com/doi/10.1111/imm.13954
  131. https://pmc.ncbi.nlm.nih.gov/articles/PMC9723951/
  132. https://journals.sagepub.com/doi/abs/10.1177/09612033241266779
  133. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.1046687/full
  134. https://pmc.ncbi.nlm.nih.gov/articles/PMC4034027/
  135. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0165415
  136. https://www.researchgate.net/publication/226017795_Flu-Like_Syndrome_and_Cytokines
  137. https://pubmed.ncbi.nlm.nih.gov/15597025/
  138. https://pubmed.ncbi.nlm.nih.gov/15468613/
  139. https://www.nature.com/articles/tp2016274
  140. https://pubmed.ncbi.nlm.nih.gov/15885359/
  141. https://pmc.ncbi.nlm.nih.gov/articles/PMC4462448/
  142. https://pmc.ncbi.nlm.nih.gov/articles/PMC9388759/
  143. https://pubmed.ncbi.nlm.nih.gov/24120833/
  144. https://pmc.ncbi.nlm.nih.gov/articles/PMC2994613/
  145. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0272826
  146. https://pubmed.ncbi.nlm.nih.gov/28579323/
  147. https://pubmed.ncbi.nlm.nih.gov/26958929/
  148. https://www.nature.com/articles/s41598-020-64865-w
  149. https://febs.onlinelibrary.wiley.com/doi/pdf/10.1111/febs.70126
  150. https://www.nature.com/articles/s41392-024-01980-4
  151. https://rupress.org/jem/article/213/13/2931/42159/Interferon-regulatory-factor-2-protects-mice-from
  152. https://pmc.ncbi.nlm.nih.gov/articles/PMC9187215/
  153. https://www.mdpi.com/2077-0383/14/18/6636
  154. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1646996/full
  155. https://pmc.ncbi.nlm.nih.gov/articles/PMC10175883/
  156. https://pmc.ncbi.nlm.nih.gov/articles/PMC10175907/
  157. https://ojrd.biomedcentral.com/articles/10.1186/s13023-025-03675-7
  158. https://www.nejm.org/doi/full/10.1056/NEJMoa1312625
  159. https://pmc.ncbi.nlm.nih.gov/articles/PMC7867893/
  160. https://www.jacionline.org/article/S0091-6749%2816%2930797-7/fulltext
  161. https://pmc.ncbi.nlm.nih.gov/articles/PMC3278554/
  162. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.00927/full
  163. https://ped-rheum.biomedcentral.com/articles/10.1186/s12969-022-00686-7
  164. https://www.sciencedirect.com/science/article/pii/S1521694224000469
  165. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.825367/full
  166. https://pmc.ncbi.nlm.nih.gov/articles/PMC5127012/
  167. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.862764/full
  168. https://www.nature.com/articles/s41598-017-02951-2
  169. https://pmc.ncbi.nlm.nih.gov/articles/PMC5281639/
  170. https://www.mdpi.com/1422-0067/15/11/21045
  171. https://www.sciencedirect.com/science/article/abs/pii/S0145305X16303548
  172. https://pubmed.ncbi.nlm.nih.gov/27780747/
  173. https://pubmed.ncbi.nlm.nih.gov/35660570/
  174. https://onlinelibrary.wiley.com/doi/10.1111/raq.12349
  175. https://hal.inrae.fr/hal-04172440v1/file/clark-2023-genomics.pdf
  176. https://avmajournals.avma.org/downloadpdf/journals/javma/199/10/javma.1991.199.10.1477.pdf
  177. https://www.mdpi.com/2076-2615/10/9/1464
  178. https://academic.oup.com/mbe/article/38/10/4546/6310749
  179. https://pmc.ncbi.nlm.nih.gov/articles/PMC10846735/
  180. https://www.researchgate.net/publication/373943939_Viperin_immunity_evolved_across_the_tree_of_life_through_serial_innovations_on_a_conserved_scaffold
  181. https://www.sciencedirect.com/science/article/pii/S0145305X17305633
  182. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2017.00209/full
  183. https://pubmed.ncbi.nlm.nih.gov/9809615/
  184. https://pmc.ncbi.nlm.nih.gov/articles/PMC126042/
  185. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.905370/full
  186. https://onlinelibrary.wiley.com/doi/10.1111/1744-7917.70109?af=R
  187. https://elifesciences.org/articles/70436
  188. https://www.researchgate.net/publication/382848748_The_immune_system_of_marine_invertebrates_Earliest_adaptation_of_animals
  189. https://pmc.ncbi.nlm.nih.gov/articles/PMC8476169/
  190. https://www.cell.com/cell-reports/fulltext/S2211-1247%2824%2901029-5
Add your contribution
Related Hubs
User Avatar
No comments yet.